Fundz

Fundz Deep Dive

Everything you need to win GSK (GlaxoSmithKline) — in one platform.

Who to reach, what to say, and why now on GSK (GlaxoSmithKline) — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on GSK (GlaxoSmithKline) — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Cambridge and GSK announce a new five-year collaboration to improve outcomes for patients with hard-to-treat kidney and respiratory diseases

Oct 21, 2024•over 1 year ago

Contract Type

partnership

LondonBiotechnologyHealth Care

Description

Cambridge and GSK have announced a new five-year collaboration, the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), focused on understanding the onset, progression, and treatment response of kidney and respiratory diseases. GSK is investing more than £50 million in this collaboration, strengthening Cambridge’s leading position in life sciences.

Company Information

Company

GSK (GlaxoSmithKline)

Location

London, England, United Kingdom

About

GSK is a global healthcare company that researches and develops a broad range of innovative medicines and vaccines. They focus on improving patient health and well-being through science and technology. GSK was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for GSK (GlaxoSmithKline)'s next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.